BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25445448)

  • 21. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
    Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
    N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW; Yeung SS
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementation.
    Leonova TA; Drozd VM; Saenko VA; Mine M; Biko J; Rogounovitch TI; Takamura N; Reiners C; Yamashita S
    Endocr J; 2015; 62(2):173-82. PubMed ID: 25374130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
    Khmara IM; Tolkachev IuV
    Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study.
    Schneider R; Schneider M; Reiners C; Schneider P
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3926-34. PubMed ID: 22977269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
    Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
    J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
    Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
    Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.
    Kim CW; Hong S; Oh SH; Lee JJ; Han JY; Hong S; Kim SH; Nam M; Kim YS
    J Bone Metab; 2015 Aug; 22(3):135-41. PubMed ID: 26389089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
    Mendonça Monteiro de Barros G; Madeira M; Vieira Neto L; de Paula Paranhos Neto F; Carvalho Mendonça LM; Corrêa Barbosa Lima I; Corbo R; Fleiuss Farias ML
    J Bone Miner Metab; 2016 Jul; 34(4):417-21. PubMed ID: 26056020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
    Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
    Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
    Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
    Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
    Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bone mineral density in patients on long-term therapy with levothyroxine].
    Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
    Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.